HealthMesothelioma

New Mesothelioma Vaccine Treatment Study Now Recruiting

Vaccines are hot in cancer research right now and a mesothelioma vaccine treatment is part of this new scientific effort.

We’ve found a new mesothelioma vaccine treatment study now recruiting participants. The study is under the auspices of the federal government’s prestigious National Cancer Institute headquartered outside of Washington D.C. in Bethesda, MD and simultaneously being conducted at top cancer centers across the United States. One of them is the Comprehensive Cancer Care Center at the University of California San Francisco.

Most of the vaccines we get throughout our lives seek to prevent serious diseases by injecting just enough of a disease to trigger immunity without making us actually sick. Cancer vaccines, including this new mesothelioma vaccine being tested, work a little differently. They aim not to prevent but to treat cancer already present. The immune response triggered by the vaccine helps by destroying tumor cells.

For this specific mesothelioma vaccine, a bacteria known as Listeria will be the active agent. It is named after Joseph Lister, an English doctor who pioneered sterile surgery.

Participants may receive maintenance doses of the mesothelioma vaccine at follow-up visits.

Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma

First received August 23, 2012

Last updated May 14, 2014

Sponsor Aduro BioTech, Inc.

Estimated Enrollment 40

Study Start Date August 2012

Estimated Completion Date December 2015

Purpose To evaluate the safety and immune response of the cancer vaccine CRS-207 followed by chemotherapy. CRS-207 is a weakened form of Listeria monocytogenes that has been genetically-modified to reduce its capacity to cause disease, while maintaining its ability to stimulate potent immune responses. This trial will evaluate whether giving CRS-207 cancer vaccine with chemotherapy will induce anti-tumor immune responses.

Primary Outcome Measures Number of patients reporting any adverse reactions; immune response to mesothelin measured at multiple times.

Eligibility

  • A confirmed diagnosis of malignant pleural mesothelioma
  • Life expectancy of more than six months
  • Not a candidate for surgery
  • No previous chemotherapy

 

Contacts and Locations

Yvonne Malory, RN

301-402-0255

[email protected]

Raffit Hassan, MD

301-451-8742

[email protected]

 

University of California at San Francisco

San Francisco, California, United States, 94115

Contact: Scott Hammond    415-885-3673    [email protected]

 

H. Lee Moffitt Cancer Center

Tampa, Florida, United States, 33612

Contact: Germaine M González-Vazquez, BS, CCRP    813-745-8350    [email protected]

 

University of Chicago Medical Center

Chicago, Illinois, United States, 60637

Contact: Peter Ostiguy, BA    773-834-1472    [email protected]

Contact: Jennifer Hull, RN, OCN    773-834-3137    [email protected]

 

National Cancer Institute

Bethesda, Maryland, United States, 20892

Contact: Yvonne Mallory, RN, BSN    301-402-0255    [email protected]

Principal Investigator: Raffit Hassan, MD

 

University of Pennsylvania Abramson Cancer Center

Philadelphia, Pennsylvania, United States, 19104

Contact: Mona Jacobs-Small, B.S., RRT, CCRC    215- 662-8632    [email protected]

Tags
Show More

Amir Hussain

Amir Hussain is the founder of Freemium World, a geek by nature and a professional Blog writer . I love to write about new technology trends, social media, hacking, blogging and much more.

Leave a Reply

Your email address will not be published. Required fields are marked *

Close